{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:54:25Z","timestamp":1784350465002,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>First\u2010 and second\u2010generation antipsychotics (FGAs and SGAs, respectively) with dopamine\u2010antagonizing properties may cause involuntary movement\u2010related adverse drug reactions (ADRs). However, the risk in the Japanese population is not well characterized. In this study, we analyzed spontaneous ADR reports from the Japanese Adverse Drug Event Report (JADER) database and evaluated the reporting odds ratios (RORs) of tardive dyskinesia (TD) and other extrapyramidal symptoms (EPS) associated with antipsychotics. SGAs were evaluated both as a whole class and as subgroups based on their primary pharmacological mode of action. From 1 April 2011 to 31 March 2020, 1\u2009197\u2009065 ADRs, including 760 TD and 6059 EPS cases, were identified for this study. By calculating RORs, risk signals were detected with both FGAs and SGAs for TD and EPS compared with non\u2010antipsychotics, with an ROR (95% confidence interval (CI)) of 153.9 (125.64\u2013188.34) with FGAs for TD and 95.3 (80.61\u2013112.65) with SGAs total for TD. No risk signals were detected for SGAs total data or any SGA subgroups versus FGAs. The ROR (95% CI) with SGAs total versus FGAs for TD was 0.62 (0.51\u20130.75), for dyskinesia: 0.55 (0.42\u20130.72), and for parkinsonism: 0.43 (0.35\u20130.52), showing that SGAs were associated with lower reporting frequency versus FGAs, but not for akathisia and dystonia. In conclusion, both FGAs and SGAs were associated with risks for TD and EPS compared with non\u2010antipsychotics in the Japanese population, and SGAs total or all SGA subgroups showed no risk signals compared with FGAs.<\/jats:p>","DOI":"10.1002\/npr2.70049","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:00:25Z","timestamp":1757703625000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reporting Frequency of Antipsychotics\u2010Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-524X","authenticated-orcid":false,"given":"Yosuke","family":"Saga","sequence":"first","affiliation":[{"name":"Medical Affairs Department Johnson &amp; Johnson  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Horio","sequence":"additional","affiliation":[{"name":"Medical Affairs Department Johnson &amp; Johnson  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih\u2010Lin","family":"Chiang","sequence":"additional","affiliation":[{"name":"Medical Affairs Department Johnson &amp; Johnson  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Wakamatsu","sequence":"additional","affiliation":[{"name":"Medical Affairs Department Johnson &amp; Johnson  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2082"},{"key":"e_1_2_12_3_1","volume-title":"Statistical Brief (Medical Expenditure Panel Survey (US)). Statistical Brief #534","author":"Ahrnsbrak R.","year":"2001"},{"key":"e_1_2_12_4_1","volume-title":"First\u2010Generation Versus Second\u2010Generation Antipsychotics in Adults: Comparative Effectiveness. Comparative Effectiveness Reviews, No. 63. Introduction","author":"Abou\u2010Setta A. M.","year":"2012"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161210790361416"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S30767"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2023.10.225"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010019\u201002269\u20108"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.NU18041BR2C"},{"issue":"9","key":"e_1_2_12_10_1","first-page":"16","article-title":"Tardive Dyskinesia Rates With Atypical Antipsychotics in Adults: Prevalence and Incidence","volume":"65","author":"Kane J. M.","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"e_1_2_12_11_1","first-page":"15","article-title":"Review of Incidence Studies of Tardive Dyskinesia Associated With Typical Antipsychotics","volume":"61","author":"Glazer W. M.","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.5414\/cp201505"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.823826"},{"issue":"9","key":"e_1_2_12_14_1","first-page":"21","article-title":"Tardive Dyskinesia Rates With Atypical Antipsychotics in Older Adults","volume":"65","author":"Jeste D. V.","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.3.414"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20579"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.2.180"},{"key":"e_1_2_12_18_1","unstructured":"Japanese Adverse Drug Event Report (JADER) database Pharmaceuticals and Medical Devices Agency. (in Japanese) accessed 5 December 2024 https:\/\/www.pmda.go.jp\/safety\/info\u2010services\/drugs\/adr\u2010info\/suspected\u2010adr\/0005.html."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12385"},{"key":"e_1_2_12_20_1","unstructured":"Neuroscience Based Nomenclature (NbN)accessed 5 December 2024 https:\/\/nbn2r.com."},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2011.04037.x"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.101485"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(23)00005\u20106"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31135\u20103"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/j.1440\u20101614.2004.01382.x"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.12.1724"},{"key":"e_1_2_12_28_1","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Kane J. M.","year":"1995"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204.pub2"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010024\u201001078\u2010z"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01072-4"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.842"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000485"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.70049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:27:49Z","timestamp":1772994469000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.70049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/npr2.70049"],"URL":"https:\/\/doi.org\/10.1002\/npr2.70049","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70049"}}